Urolog. pro Praxi, 2007; 8(5): 234-239

Combination drug therapy in men with lower urinary tract symptoms: contemporary status

doc. MUDr. Jozef Marenčák PhD
Urologické oddelenie NsP Skalica

Paper makes a brief summary of relevant information concerning combination pharmacotherapy in men with lower urinary tract symptoms (LUTS) and informs about indications, effectiveness, adverse effects of various types of combination pharmacological treatment. Diagnosis and therapy of LUTS must be comprehensive and individualized. Combination therapy of an alpha-blocker with a 5alpha-reductase-inhibitor seems to be more beneficial and durable than the monotherapy of either substance in symptomatic men with high risk of progression of benign prostate hyperplasia. Indications for using of combination alpha-blocker + 5alpha-reductase-inhibitor are: symptomatic men with prostate volume > 30 (40) ml, prostate specific antigen (PSA) > 1,4–1,6 ng/ml, post void residual urine > 40 ml and in a cases of ineffectiveness of medicamentous monotherapy. The combination of an alpha-adrenergic receptor antagonist and 5-alpha reductase inhibitor is appropriate and effective treatment for patients with LUTS associated with demonstrable prostatic enlargement. All combinations of an alpha-blocker and 5-alpha reductase inhibitor would be equally effective. The combination of doxazosin and finasteride is the best tested regarding safety and afficacy. The clinical utility of this combination therapy take account of the balance between cost efficacy and additional side effects. The management of OAB occuring in the presence of BOO is the subject of ongoing research. Antimuscarinic therapy as solo therapy can not be recommended for routinne use. Combination therapy of antimuscarinic and alpha blocker may be efficacious. There is insufficient evidence to recommend that the combination of phosphodiesterase inhibitors and an alpha adrenoreceptor antagonists has any advantage over monotherapy with alpha-blocker alone. Combination treatment (alpha-blocker/or 5-alpha reductase inhibitor + antidiuretic hormone/desmopressin/seems to be effective and appropriate for patients with BPH and nocturnal polyuria. Paper makes a review of new medical developments and targets in the management of LUTS in adult men.

Keywords: lower urinary tract symptoms, men, combination drug therapy

Published: October 23, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. Combination drug therapy in men with lower urinary tract symptoms: contemporary status. Urol. praxi. 2007;8(5):234-239.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M et al. Report from the Standardisation subcommittee of the International Continence Society. Neurourol. Urodyn, 21, 2002, č. 1, s. 167-178. Go to original source... Go to PubMed...
    2. Abrams P, D´Ancona C, Griffiths D et al. Lower urinary tract symptoms: etiology, patient assessment and predicting outcome from therapy. In: Mc Connel J, Abrams P, Denis L et al. Male lower urinary tract dysfunction - evaluation and management. Paris - France, Health Publications, 2006, pp. 69-142.
    3. Andersson KE, Cruz F, Klocker H et al. New therapeutic targets in BPH and LUTS (research priorities). In: Mc Connel J, Abrams P, Denis L et al. Male lower urinary tract dysfunction - evaluation and management. Paris - France, Health Publications, 2006, pp. 299-324.
    4. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur. Urol., 43, 2003, č. 1, s. 1-5. Go to original source... Go to PubMed...
    5. Artibani W. Overactive bladder: new perspectives. Eur. Urol., 1, 2002, Suppl. 4, s. 1-30. Go to original source...
    6. Baldwin K, Ginsberg P, Roehrborn C et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology, 58, 2001, č. 2, s. 203-209. Go to original source... Go to PubMed...
    7. Barkin J, Guimaraes M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur. Urol., 44, 2003, č. 4, s. 461-466. Go to original source... Go to PubMed...
    8. Breza J, Kliment J, Marenčák J a ost. Noktúria: jej klinický význam a vplyv na kvalitu života. Med. Monitor, 2006, č. 4, s. 1-6.
    9. Brookes S, Donovan J, Peters T et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ, 324, 2002, č. 4, s. 1059-1061. Go to original source... Go to PubMed...
    10. Cvetkovic R, Plosker G. Desmopressin: in adults with nocturia. Drugs, 65, 2005, č. 2, s. 99-107. Go to original source... Go to PubMed...
    11. Chapple C, Artibani W, Berges R et al. New medical developments in the management of LUTS in adult men. In: Mc Connel J, Abrams P, Denis L et al. Male lower urinary tract dysfunction - evaluation and management. Paris - France, Health Publications, 2006, pp. 143-194.
    12. Chapple C. BHP disease management: introduction and concluding remarks. Eur. Urol., 36, 1999, suppl. 3, s. 1-6. Go to original source... Go to PubMed...
    13. Kaplan S, Walmsley K, TE A. Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J. Urol., 171, 2004, č. 4, s. 917. Go to original source...
    14. Kirby S, Mc Connell J. Benign prostatic hyperplasia. Oxford - England, Health Press Limited, 2005, pp. 1-92.
    15. Lee J, Kim H, Lee S et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int., 94, 2004, č. 6, s. 817-820. Go to original source... Go to PubMed...
    16. Lose G, Mattiasson A, Walter S et al. Clinical experiences with desmopressin for long - term treatment of nocturia. J. Urol., 172, 2004, č. 6, s. 1021-1025. Go to original source... Go to PubMed...
    17. Madersbacher S, Alivizatos G, Nordling J et al. EAU 2004 guidelines on assessment, therapy and follow - up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur. Urol., 46, 2004, č. 5, s. 547-554. Go to original source... Go to PubMed...
    18. Marenčák J. Súčasný stav výskytu, diagnostiky a liečby urgentnej inkontinencie moču. Súčasná Klinická Prax, 2, 2005, č. 2, s. 5-12.
    19. Mattiasson A, Abrams P, Van Kerrebroeck P et al. Efficacy od desmopressin in the treatment of nocturia: a double - blind placebo - controlled study in men. BJU Intern., 89, 2002, č. 4, s. 855-862. Go to original source... Go to PubMed...
    20. Mc Connell J, Roehrborn C, Bautista O et al. Medical therapy of prostatic symptoms (MTOPS) research group. The long - term effect of doxazosin, finasteride, and combination therapy on the clinical progression og benign prostatic hyperplasia. N. Engl. J. Med., 349, 2003, č. 25, s. 2387-2398. Go to original source... Go to PubMed...
    21. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dsyfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol., 44, 2003, č. 5, s. 637-649. Go to original source... Go to PubMed...
    22. Rosette J, Alivizatos G, Madersbacher S et al. Guidelines on benign prostatic hyperplasia. Arnhem - Nederlands, 2007, European Association of Urology, pp. 1-59.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.